By the Numbers

Endo has approximately 3,000 employees worldwide

Endo’s total 2017 revenue was $3.47 billion

Sterile Injectables revenues increased 23% to full-year sales of $654 million

U.S. Specialty Branded Pharmaceuticals performance increased 11% to full-year sales of $453 million

XIAFLEX® achieved full‑year sales of $213 million, a 12% increase vs. prior year

U.S. Generic Pharmaceuticals has a portfolio of over 280 product families

U.S. Generic Pharmaceuticals has over 175 products in our pipeline including approximately 100 ANDAs pending with the FDA, of which more than 1/3 represent first-to-file or first-to-market opportunities

Endo announced the initiation of two pivotal Phase 3 clinical trials of collagenase clostridium histolyticum (CCH) for the treatment of cellulite. Cellulite has been reported in 85% to 98% of post-pubertal females and affects women of all races and ethnicities

Company Information